Strongbridge raises $25M in a downsized IPO

Drug developer Strongbridge Biopharma ($SBBP) cleared $25 million in an IPO, bringing in less than a third of the cash it once sought as biotech companies continue to struggle on Wall Street. The company, formerly known as Cortendo, moved 2.5 million shares at $10 each, pricing an offering well below the $86 million it craved last month. Strongbridge is working through Phase III with COR-003, a treatment for Cushing's syndrome, and expects to report data in 2017. Release

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.